Santhera Pharmaceuticals Valuation
| SANN Stock | CHF 9.25 0.33 3.44% |
At this time, the company appears to be overvalued. Santhera Pharmaceuticals has a current Real Value of ₣7.61 per share. The regular price of the company is ₣9.25. Our model measures the value of Santhera Pharmaceuticals from inspecting the company fundamentals such as Shares Owned By Insiders of 18.77 %, current valuation of 58.16 M, and Return On Equity of -13.16 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Santhera Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Santhera Pharmaceuticals is based on 3 months time horizon. Increasing Santhera Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Santhera stock is determined by what a typical buyer is willing to pay for full or partial control of Santhera Pharmaceuticals Holding. Since Santhera Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Santhera Stock. However, Santhera Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.25 | Real 7.61 | Hype 9.25 |
The intrinsic value of Santhera Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Santhera Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Santhera Pharmaceuticals Holding helps investors to forecast how Santhera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Santhera Pharmaceuticals more accurately as focusing exclusively on Santhera Pharmaceuticals' fundamentals will not take into account other important factors: Santhera Pharmaceuticals Total Value Analysis
Santhera Pharmaceuticals Holding is at this time anticipated to have takeover price of 58.16 M with market capitalization of 50.45 M, debt of 27 M, and cash on hands of 21.21 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Santhera Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
58.16 M | 50.45 M | 27 M | 21.21 M |
Santhera Pharmaceuticals Investor Information
About 19.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.63. Santhera Pharmaceuticals last dividend was issued on the 8th of September 2022. The entity had 10:1 split on the 2nd of July 2023. Based on the key indicators related to Santhera Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Santhera Pharmaceuticals Holding is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Santhera Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Santhera is to check how much profit was generated for every dollar of assets it reports. Santhera Pharmaceuticals has a negative utilization of assets of -0.49 %, losing ₣0.004918 for each franc of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each franc of assets it has. In other words, asset utilization of Santhera Pharmaceuticals Holding shows how discouraging it operates for each franc spent on its assets.Santhera Pharmaceuticals Ownership Allocation
Santhera Pharmaceuticals shows a total of 61.81 Million outstanding shares. Santhera Pharmaceuticals has 18.77 % of its outstanding shares held by insiders and 3.5 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Santhera Pharmaceuticals Profitability Analysis
Net Loss for the year was (55.53 M) with loss before overhead, payroll, taxes, and interest of (5.36 M).About Santhera Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Santhera Pharmaceuticals. We calculate exposure to Santhera Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Santhera Pharmaceuticals's related companies.Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland. SANTHERA N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 114 people.
8 Steps to conduct Santhera Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Santhera Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Santhera Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Santhera Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Santhera Pharmaceuticals' revenue streams: Identify Santhera Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Santhera Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Santhera Pharmaceuticals' growth potential: Evaluate Santhera Pharmaceuticals' management, business model, and growth potential.
- Determine Santhera Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Santhera Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.